Cargando…

Midterm Outcome of Femoral Artery Stenting and Factors Affecting Patency

PURPOSE: The purpose of this study was to evaluate the early and midterm results of superficial femoral artery (SFA) stenting with self-expanding nitinol stents and to identify the factors affecting patency. MATERIALS AND METHODS: SFA stenting was performed in 165 limbs of 117 patients from January...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jae Seoung, Park, Keun-Myoung, Jeon, Yong Sun, Cho, Soon Gu, Hong, Kee Chun, Shin, Woo Young, Choe, Yun-Mee, Shin, Seok-Hwan, Kim, Kyung Rae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Vascular Specialist International 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694182/
https://www.ncbi.nlm.nih.gov/pubmed/26719837
http://dx.doi.org/10.5758/vsi.2015.31.4.115
Descripción
Sumario:PURPOSE: The purpose of this study was to evaluate the early and midterm results of superficial femoral artery (SFA) stenting with self-expanding nitinol stents and to identify the factors affecting patency. MATERIALS AND METHODS: SFA stenting was performed in 165 limbs of 117 patients from January 2009 to December 2013. Patients were followed-up for the first occurrence of occlusion or stenosis based on computed tomography and duplex scan results and a decrease in ankle brachial index of >15%. RESULTS: During the follow-up period (mean, 15.3±3.2 months), no early thrombotic reocclusions occurred within 30 days, but in-stent restenosis developed in 78 limbs. The primary patency rates at 6, 12, 18, and 24 months were 78%, 66%, 42%, and 22%, respectively, and the secondary patency rates were 85%, 72%, 58%, and 58%, respectively. TASC II C or D lesions, stent length >8 cm, number of patent tibial arteries and diabetes were significantly associated with reintervention. CONCLUSION: The midterm results of stenting for SFA occlusive disease were disappointing because the primary and secondary patency rates at two years were 22% and 58%, respectively. Reintervention after SFA stenting remains a major problem, particularly in patients with diabetes mellitus or long TASC II C or D lesions.